Made With Uberflip Content Marketing

Live Event Coverage

The latest news and dealmakers from global life science partnering events

  • Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD7:09

    Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD

    Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Spea

    Watch Video
  • Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry8:15

    Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry

    With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global dir

    Watch Video
  • Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health6:18

    Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health

    Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development.

    Watch Video
  • Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets6:07

    Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

    Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outli

    Watch Video
  • Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 20174:24

    Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

    An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,

    Watch Video
  • Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception9:11

    Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

    With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia

    Watch Video
  • Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America8:28

    Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America

    As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovatio

    Watch Video
  • Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology10:37

    Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

    Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProN

    Watch Video
  • Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were...

    Read
  • Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery8:05

    Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery

    Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an intervi

    Watch Video
  • Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity9:36

    Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

    Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In

    Watch Video
  • Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML12:05

    Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

    Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic hea

    Watch Video
  • Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta10:13

    Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

    Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in add

    Watch Video
  • Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals8:15

    Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals

    Speaking at the 2017 Biotech Showcase™ in San Francisco, Gruenenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by

    Watch Video
  • Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and...

    Read
  • Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development. Read...

    Read
  • Digital Medicine Showcase 2017: State of the Digital Medicine Industry58:35

    Digital Medicine Showcase 2017: State of the Digital Medicine Industry

    Tools that will usher in a new age of healthcare are changing the game by creating more effective R&D processes, strengthening the patient-physician relationship, and simultaneously enabling individua

    Watch Video
  • #DigMedShow & #MedtechShow 2017: Verily, Qualcomm, Proteus, Johnson & Johnson, Hogan Lovells1:23:51

    #DigMedShow & #MedtechShow 2017: Verily, Qualcomm, Proteus, Johnson & Johnson, Hogan Lovells

    A holistic approach is critical to creating viable solutions for an efficient and effective healthcare system. With representatives across several key sectors, this panel examines the impact of non-tr

    Watch Video
  • Biotech Showcase™ 2017: Journalist Wrap: Biotech 2017: Pulse, prognosis and the press46:48

    Biotech Showcase™ 2017: Journalist Wrap: Biotech 2017: Pulse, prognosis and the press

    As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and beyo

    Watch Video
  • Digital Medicine Showcase 2017: Fireside Chat with Bryan Roberts48:50

    Digital Medicine Showcase 2017: Fireside Chat with Bryan Roberts

    Gain insights from one of the industry’s most successful investors, featured on the Forbes Midas list eight times running (2008–2016).

    Watch Video
  • loading
    Loading More...